Edition:
United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

55.47USD
9 Dec 2016
Change (% chg)

$-0.28 (-0.50%)
Prev Close
$55.75
Open
$56.19
Day's High
$57.28
Day's Low
$55.44
Volume
630,599
Avg. Vol
1,070,302
52-wk High
$80.71
52-wk Low
$27.14

Ehrich, Elliot 

Dr. Elliot W. Ehrich M.D. is Executive Vice President, Research and Development and Chief Medical Officer of Alkermes Plc. Prior to assuming his current position, from September 16, 2011 until February 2015, Dr. Ehrich was our Senior Vice President, Research and Development, and Chief Medical Officer. From May 2007 to September 16, 2011, Dr. Ehrich served as Senior Vice President, Research and Development, and Chief Medical Officer of Alkermes, Inc. Prior to this Dr. Ehrich served as Vice President, Science Development and Chief Medical Officer of Alkermes, Inc. Prior to joining Alkermes in 2000, Dr. Ehrich spent seven years at Merck & Co., Inc. ("Merck"), a publicly traded pharmaceutical company, overseeing the clinical development and registration of novel pharmaceuticals. Dr. Ehrich is a Fellow of the American College of Rheumatology and has had numerous publications in peer-reviewed journals. Dr. Ehrich worked as a research associate at the European Molecular Biology Laboratory in Heidelberg, Germany before attending medical school. Dr. Ehrich is also a member of the scientific advisory boards for Aileron Therapeutics and Heptares Therapeutics, both privately held biopharmaceutical companies. Dr. Ehrich is also an advisor to TrialNetworks.com.

Basic Compensation

Total Annual Compensation, USD 468,120
Restricted Stock Awards, USD 707,400
Long-Term Incentive Plans, USD --
All Other, USD 2,013,240
Fiscal Year Total, USD 3,188,760

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 312,247 2,622,080.00
Name Fiscal Year Total

Richard Pops

10,448,400

Shane Cooke

4,646,970

James Frates

2,565,400

Gordon Pugh

1,965,720

Kathryn Biberstein

3,041,000

Elliot Ehrich

3,188,760
As Of  30 Dec 2014